Report from the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia

Overview

Journal Schizophr Bull

Publisher Oxford University Press

Specialty Psychiatry

Date 2010 Mar 3

PMID 20194249

Citations 30

Authors

Richard S E Keefe

Sophia Vinogradov

Alice Medalia

Steven M Silverstein

Morris D Bell

Dwight Dickinson

Joseph Ventura

Stephen R Marder

T Scott Stroup

Affiliations

Soon will be listed here.

Abstract

The National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project and related efforts have stimulated the initiation of several studies of pharmacologic treatments for cognitive impairment in schizophrenia. Cognitive remediation may provide an excellent platform for the provision of new learning opportunities and the acquisition of new skills for patients who are engaged in pharmacologic trials to improve cognition. However, it is not clear how a cognitive remediation intervention would be employed in multisite clinical trials. A meeting of experts on cognitive remediation and related methodological topics was convened to address the feasibility and study design issues for the development of a multisite trial of cognitive remediation in schizophrenia called the Cognitive Remediation in the Schizophrenia Trials Network study. This report details the findings from this meeting, which included the following 4 conclusions. (1) A multisite trial of a cognitive remediation intervention using a network of diverse research sites would be of great scientific value. (2) Various interventions could be employed for this multisite trial. (3) Programs that do not address key motivational and interpersonal aspects of cognitive remediation may benefit from supplementation with "bridging groups" that allows patients to meet with others and to apply their newly acquired cognitive skills to everyday life. (4) Before a multisite efficacy trial is initiated, a pilot study could demonstrate the feasibility of conducting a trial using a cognitive remediation intervention.

Citing Articles

The clock is ticking on schizophrenia: a study protocol for a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disability.

Mercuriali G, Lodde L, Paribello P, Sapienza J, Corona A, Ave C Front Psychiatry. 2024; 15:1451678.

PMID: 39540006 PMC: 11557306. DOI: 10.3389/fpsyt.2024.1451678.

Effectiveness of Virtual - Compensatory Cognitive Training (V-CCT) for improving cognition in persons with schizophrenia - a multi- centre randomized controlled trial.

Sims S, Kantipudi S, Ashok Y, Nisha B, Gopal S, Joseph E Trials. 2024; 25(1):736.

PMID: 39487475 PMC: 11528983. DOI: 10.1186/s13063-024-08568-x.

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.

Rosenbrock H, Desch M, Wunderlich G Eur Arch Psychiatry Clin Neurosci. 2023; 273(7):1557-1566.

PMID: 36971864 PMC: 10465677. DOI: 10.1007/s00406-023-01576-z.

Public stigma profile toward mental disorders across different university degrees in the University of Valencia (Spain).

Ruiz J, Fuentes-Dura I, Lopez-Gilberte M, Dasi C, Pardo-Garcia C, Fuentes-Duran M Front Psychiatry. 2022; 13:951894.

PMID: 36032229 PMC: 9411748. DOI: 10.3389/fpsyt.2022.951894.

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Miskowiak K, Seeberg I, Jensen M, Balanza-Martinez V, Bonnin C, Bowie C Bipolar Disord. 2022; 24(4):354-374.

PMID: 35174594 PMC: 9541874. DOI: 10.1111/bdi.13193.

References

Bell M, Bryson G, Greig T, Fiszdon J, Wexler B . Neurocognitive enhancement therapy with work therapy: Productivity outcomes at 6- and 12-month follow-ups. J Rehabil Res Dev. 2006; 42(6):829-38. DOI: 10.1682/jrrd.2005.03.0061. View

McDermott B . Development of an instrument for assessing self-efficacy in schizophrenic spectrum disorders. J Clin Psychol. 1995; 51(3):320-31. View

Kern R, Glynn S, Horan W, Marder S . Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009; 35(2):347-61. PMC: 2659313. DOI: 10.1093/schbul/sbn177. View

Green M . What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996; 153(3):321-30. DOI: 10.1176/ajp.153.3.321. View

Velligan D, Diamond P, Glahn D, Ritch J, Maples N, Castillo D . The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). Psychiatry Res. 2007; 151(1-2):55-66. DOI: 10.1016/j.psychres.2006.10.007. View

Wykes T, Reeder C, Landau S, Everitt B, Knapp M, Patel A . Cognitive remediation therapy in schizophrenia: randomised controlled trial. Br J Psychiatry. 2007; 190:421-7. DOI: 10.1192/bjp.bp.106.026575. View

Choi J, Medalia A . Factors associated with a positive response to cognitive remediation in a community psychiatric sample. Psychiatr Serv. 2005; 56(5):602-4. DOI: 10.1176/appi.ps.56.5.602. View

Fisher M, Holland C, Subramaniam K, Vinogradov S . Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr Bull. 2009; 36(4):869-79. PMC: 2894606. DOI: 10.1093/schbul/sbn170. View

Wykes T, Steel C, Everitt B, Tarrier N . Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2007; 34(3):523-37. PMC: 2632426. DOI: 10.1093/schbul/sbm114. View

10.

McGurk S, Green M, Wirshing W, Wirshing D, Marder S, Mintz J . Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res. 2004; 68(2-3):225-33. DOI: 10.1016/S0920-9964(03)00123-3. View

11.

Tarrier N, Wykes T . Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale?. Behav Res Ther. 2004; 42(12):1377-401. DOI: 10.1016/j.brat.2004.06.020. View

12.

Buchanan R, Davis M, Goff D, Green M, Keefe R, Leon A . A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005; 31(1):5-19. DOI: 10.1093/schbul/sbi020. View

13.

Keefe R, Bilder R, Davis S, Harvey P, Palmer B, Gold J . Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007; 64(6):633-47. DOI: 10.1001/archpsyc.64.6.633. View

14.

Heinrichs R, Zakzanis K . Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998; 12(3):426-45. DOI: 10.1037//0894-4105.12.3.426. View

15.

Wykes T, Huddy V . Cognitive remediation for schizophrenia: it is even more complicated. Curr Opin Psychiatry. 2009; 22(2):161-7. DOI: 10.1097/YCO.0b013e328322fbf4. View

16.

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

17.

Fisher M, Holland C, Merzenich M, Vinogradov S . Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry. 2009; 166(7):805-11. PMC: 2720319. DOI: 10.1176/appi.ajp.2009.08050757. View

18.

Goldberg T, Goldman R, Burdick K, Malhotra A, Lencz T, Patel R . Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry. 2007; 64(10):1115-22. DOI: 10.1001/archpsyc.64.10.1115. View

19.

Twamley E, Savla G, Zurhellen C, Heaton R, Jeste D . Development and Pilot Testing of a Novel Compensatory Cognitive Training Intervention for People with Psychosis. Am J Psychiatr Rehabil. 2009; 11(2):144-163. PMC: 2636722. DOI: 10.1080/15487760801963678. View

20.

Medalia A, Richardson R . What predicts a good response to cognitive remediation interventions?. Schizophr Bull. 2005; 31(4):942-53. DOI: 10.1093/schbul/sbi045. View